|
New data released at the annual meeting of the American PsychiatricAssociation show that patients with unipolar, non-psychotic MajorDepressive Disorder (MDD) receiving transcranial magneticstimulation (TMS) with NeuroStar TMS Therapy® achievedsignificant improvements in both depression symptoms and in quality of life measurements. Overall, 58 percentof patients achieved a positive response to NeuroStar TMS therapy,with 37 percent of patients achieving remission from theirdepression. After an average of five weeks of NeuroStar treatment, thepercentage of patients reporting extreme problems with anxiety and depression decreased by 42.2 percent, demonstrating areduction in depression symptomatology. For overall treatmenteffect, the percentage of patients reporting no problems inperforming usual activities improved by 30.5 percent. "The improvements we observed show that non-drug therapy withNeuroStar TMS not only reduces the symptomatic suffering ofpatients, but lessens the disability of depression with importantimplications for these individuals' ability to return tofunctioning effectively at home, in the workplace, and in thecommunity," said Ian A. Cook, M.D., Semel Institute forNeuroscience and Human Behavior at the University of California,Los Angeles. In the open label study, which involved 307 patients receivingacute treatment with NeuroStar TMS, patients experiencedstatistically-significant improvement across physical and mentalvariables as measured by the Short Form 36-Item Questionnaire(SF-36). The SF-36 is a multi-purpose, short-form health surveythat evaluates functional health and well-being of disease amongeight variables including physical functioning, role limitationsdue to physical problems, bodily pain, general health, vitality,social functioning, role limitations due to emotional problems and mental health. After five weeks of acute TMS therapy, the most drasticimprovement was seen in the mental component summary score, whichmore than doubled from 16.6 prior to therapy to 33.5 after therapy. Similarly, self-reported quality of life measures significantlyimproved with TMS therapy compared to baseline according to theEuroQol Questionnaire (EQ-5D), a standardized instrument that wasused to evaluate the effect of TMS therapy on the quality of lifeof patients. At the end of acute treatment with TMS, the greatestimprovements in EQ-5D dimensions were observed among patients whoindicated no problems with "usual activities" (14.3 percent pre-TMSvs. 44.8 percent post-TMS), "anxiety/depression" (1.6 percentpre-TMS vs. 30.1 percent post-TMS) and "pain/discomfort" (39.4percent pre-TMS vs. 52.8 percent post-TMS). In other EQ-5Ddimensions, 81.8 percent of patients reported no problems with"mobility" following TMS treatment vs. 68.7 percent at baseline;87.1 percent of patients reported no problems with "self-care"following TMS treatment vs. 72.6 percent at baseline. "These data reinforce the clinical efficacy of TMS Therapy as aviable option for patients living with major depression who havenot achieved or maintained symptom improvement with oralantidepressants," said H. Brent Solvason, M.D., Stanford UniversityMedical Center. "The most meaningful takeaway for patients is thatTMS Therapy has the potential to make them feel better, in additionto potentially allowing them to experience a level of physical andsocial functionality they haven't had with their depression." About Transcranial Magnetic Stimulation TMS is a non-invasive, non-systemic therapeutic device thatdelivers magnetic resonance imaging (MRI)-strength, pulsed,magnetic fields to induce an electronic current in a localizedregion of the cerebral cortex, the part of the brain that controlsmood. NeuroStar TMS Therapy is the first and only TMS therapy formajor depressive disorder cleared by the U.S. Food and DrugAdministration (FDA) that has been proven to achieve remissionwithout systemic side effects in patients who have not found reliefwith antidepressant medication. About Depression Depression is a serious illness that affects about 20 millionAmericans annually. People with depression may experience a rangeof physically and emotionally debilitating symptoms, includinganxiousness, sadness, irritability, fatigue , changes in sleep patterns, loss of interest in previouslyenjoyable activities and digestive problems. It is estimated thatabout four million patients do not benefit from standard treatmentsfor depression, even after repeated treatment attempts. About the Study The clinical trial was a multi-site, naturalistic, observationalstudy involving 307 patients receiving acute treatment with TMStherapy across 43 clinical practices. All treatments were initiatedusing the NeuroStar TMS Therapy® System (Neuronetics, Inc.,Malvern, PA, USA). The study is posted on www.clinicaltrials.gov , listing number NCT 01114477. Additional References Citations. We are high quality suppliers, our products such as China Hydraulic Blanking Press , Cold Extrusion Press Manufacturer for oversee buyer. To know more, please visits Punch Press Machine.
Related Articles -
China Hydraulic Blanking Press, Cold Extrusion Press Manufacturer,
|
